Initially, Novo Nordisk pursued covering its flagship GLP-1 Wegovy under Medicaid in multiple states, arguing long-term cost savings from obesity reduction ( [33] )
For this purpose, truncated HGF, anti-HGF neutralizing antibodies, and an uncleavable form of HGF have been utilized so far
In conclusion, in the treatment process of improving sarcopenia with GLP-1RAs, clinicians should formulate individualized plans, closely monitor the patients weight, nutritional intake and changes in body composition, and regularly assess muscle mass using tools such as ultrasound and bioelectrical impedance analysis, so as to adjust the plan in a timely manner [70, 71]
Clinical Perspective "GLP-1 medications can offer real short-term benefits in terms of appetite reduction and early weight loss, but it is important to have realistic expectations about what happens when stopping GLP-1 medication," says Alessandro Grenci, Superintendent Pharmacist at Medino
doi: 10.1016/0009-8981(85)90020-8
